- Market Capitalization, $K 2,236,431
- Shares Outstanding, K 66,799
- Annual Sales, $ 4,740 K
- Annual Income, $ -163,920 K
- 60-Month Beta 0.55
- Price/Sales 468.59
- Price/Cash Flow N/A
- Price/Book 3.34
|Period||Period Low||Period High||Performance|
| || |
+4.82 (+16.94%)since 11/08/23
| || |
+17.30 (+108.33%)since 09/08/23
| || |
+15.68 (+89.14%)since 12/08/22
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END
USA News Group – Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s...
Despite good results in phase 3 trials, there are barriers to its drug candidate's success.
A positive late-stage trial readout fueled a major rally in the drugmaker's shares.
What you need to know… The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.67%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.19%....
The biotech company reported positive phase 3 trial results.
What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.43%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.58%. Stock...
Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are up +0.47%, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are up +0.74%. Stock index futures this morning are moderately higher on...
September S&P 500 futures (ESU23) are up +0.42%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.55% this morning as remarks from Treasury Secretary Janet Yellen bolstered hopes that the U.S....
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -3.66% and 325.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...
|Crinetics Pharmaceuticals Inc|
|DWA Healthcare Momentum Invesco ETF|
|Virtus Lifesci Biotech Clinical Trials ETF|
|Alps Medical Breakthroughs ETF|
|S&P Biotech SPDR|
|FT Multi-Manager Small Cap Opportunities ETF|
|3rd Resistance Point||34.45|
|2nd Resistance Point||34.00|
|1st Resistance Point||33.64|
|1st Support Level||32.83|
|2nd Support Level||32.38|
|3rd Support Level||32.02|